SPOTLIGHT: Acambis contract offers long-term funding
The announcement that Acambis has won a $425 million, 10-year contract to supply the U.S. government with its smallpox vaccine, along with a new share placement, will provide the company with enough cash to fund operations for the medium term. To win the contract, Acambis had to agree to produce the vaccine in the U.S. Report
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight